Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

Rhea-AI Summary

Ultragenyx (NASDAQ: RARE) will host a conference call at 5:00 p.m. ET on Tuesday, November 4, 2025 to discuss third quarter 2025 financial results and a corporate update for the period ended September 30, 2025.

The live webcast and replay will be available at https://ir.ultragenyx.com/events-presentations. The replay will remain available for three months.

News Market Reaction – RARE

-0.52%

-0.52% Session close to close

In the Oct 29 session, RARE declined 0.52%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NOVATO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, November 4, 2025, to discuss its financial results and corporate update for the quarter ending September 30, 2025.

The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx

Investors
Joshua Higa
ir@ultragenyx.com

Media
Jess Rowlands
media@ultragenyx.com

FAQ

When is Ultragenyx (RARE) scheduled to report Q3 2025 results?

Ultragenyx will host a conference call at 5:00 p.m. ET on November 4, 2025 to discuss Q3 2025 results for the quarter ended September 30, 2025.

How can investors listen to the Ultragenyx (RARE) Q3 2025 earnings call?

Investors can access the live webcast and replay at https://ir.ultragenyx.com/events-presentations.

How long will the replay of Ultragenyx (RARE) Q3 2025 call be available?

The replay will be available for three months after the call.

What will Ultragenyx (RARE) discuss on the November 4, 2025 call?

The company will discuss its third quarter 2025 financial results and provide a corporate update for the quarter ended September 30, 2025.

Is the Ultragenyx (RARE) webcast free to access for the public?

Yes, the live webcast and replay are available publicly at the company investor website listed above.